2024 CBIIC in Guangzhou on November 30 - December 1, 2024.

WU Xiaobin

Dr. Xiaobin Wu has more than 25 years of rich experience in pharmaceutical industry, including 17 years leading China operations of multinational companies, with expertise in integrated research and development, strategy, commercialization, and general management. Before joining BeiGene, Dr. Wu served as the Country Manager of Pfizer China and Regional President of Pfizer Essential Health in Greater China Region.

Prior to Pfizer, Dr. Wu served as President and Managing Director of Wyeth China and Hong Kong from 2004 to 2009, and the General Manager of Bayer Healthcare in China from 2001 to 2004.

Dr. Wu has been elected as the Vice Chairman of RDPAC in China since 2008. He is the Vice Chairman of the Pharmaceutical Chamber of Commerce of China’s National Association of Industry & Commerce; the Executive Vice Chairman of the Chinese Pharmaceutical Enterprise Association. He is also a research fellow at Research Center of National Drug Policy and Ecosystem. Recently he has been voted as “Person of the Year” in Healthy China Award 2017, “2017 Top 10 Most Influential Person in Chinese Healthcare Industry” and “2017 Social Responsibility Eminent Person Award”

Dr. Wu holds Ph.D. in Biochemistry and Pharmacology and a master degree in Molecular Biology from the University of Konstanz in Germany.